SR One Capital Management Discloses 6.4% Stake in Veradermics Following IPO
MANE sits 37% above its 52-week low of $32.
Summary
SR One Capital Management and affiliated funds, along with Simeon George, have disclosed a 6.4% beneficial ownership stake in Veradermics, Inc. following the company's recent Initial Public Offering.
Key Events · Ownership and Investor Activity · MANE
-
Significant Ownership Stake Disclosed
SR One Capital Management, its affiliated funds, and Simeon George now beneficially own 2,401,868 shares, representing 6.4% of Veradermics' common stock.
-
Pre-IPO Investment and IPO Participation
The stake results from the conversion of Series C Convertible Preferred Stock, acquired in private transactions for approximately $25 million, and an additional purchase of 450,000 shares at the IPO price of $17.00 per share.
-
Investment for Long-Term Purposes
The shares were acquired for investment purposes, with no current plans for extraordinary corporate transactions or changes in the company's board or management.
-
Subject to Lock-up Agreement
The reporting persons are subject to a 180-day lock-up period from February 3, 2026, restricting the sale or transfer of their shares without underwriter consent.
Analysis · MANE · Life Sciences
This Schedule 13D filing provides crucial transparency regarding a significant institutional investor's foundational stake in Veradermics following its recent IPO. SR One Capital Management, a venture capital firm, converted substantial pre-IPO preferred stock holdings and participated in the IPO, demonstrating strong conviction in the company's long-term prospects. The disclosure of a major institutional investor holding over $100 million in shares (at current market price) is a positive signal, especially as the stock trades near its 52-week high. This filing complements recent Form 4 disclosures showing other directors and 10% owners also making substantial purchases post-IPO, collectively indicating robust insider and institutional confidence in the newly public company.
At the time of this filing, MANE was trading at $43.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $32.00 to $44.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.